Publications by authors named "Y Le Mer"
Article Synopsis
- - The study investigates the link between early reperfusion (ER) and visual outcomes in patients with central retinal artery occlusion (CRAO) or branch retinal artery occlusion (BRAO), finding that ER occurs in nearly 50% of cases.
- - Researchers included 70 patients, mostly with CRAO, and assessed visual outcomes at one month, revealing that those with ER had better visual acuity and quality of life compared to those without it.
- - The findings suggest that therapies aimed at enhancing ER could significantly improve clinical outcomes for patients suffering from CRAO or BRAO.
Purpose: To compare the refractive outcomes and the complications of implantation surgery by the Carlevale IOL to the Artisan iris-claw IOL.
Methods: Retrospective comparative study of consecutive surgical cases between 2019 and 2021 in our tertiary centre in Paris, France.
Results: We included 142 eyes in the Artisan group and 63 in the Carlevale group.
Prevalence and significance of fovea plana in patients with epiretinal membrane.
Eur J Ophthalmol
July 2024
Introduction: Fovea plana is indicative of an immature inner retina, yet its association with epimacular membrane (ERM) remains unexplored. This study aims to investigate the prevalence of fovea plana in the contralateral eye of patients diagnosed with ERM.
Methods: A retrospective analysis was conducted on consecutive patients in a monocentric tertiary ophthalmic department between January and April 2021.
Background: After idiopathic epiretinal membrane (iERM) removal, it is unclear whether the internal limiting membrane (ILM) should be removed. The objective was to assess if active ILM peeling after iERM removal could induce microscotomas.
Methods: The PEELING study is a national randomised clinical trial.
Objective: To assess the efficacy and safety of the PRIMA neurostimulation system with a subretinal microchip for improving visual acuity (VA) in patients with geographic atrophy (GA) due to age-related macular degeneration (AMD) at 48-months postimplantation.
Design: Feasibility clinical trial of the PRIMA subretinal prosthesis in patients with atrophic AMD, measuring best-corrected ETDRS VA (Clinicaltrials.govNCT03333954).